[1] Biosensor technologies for natural medicine discovery: current advances, challenges, and future directions[J], TrAC Trends in Analytical Chemistry. 194 (2026) 118498（SCI Q1）
[2] Comprehensive Review of the Application of Aptamer-Based Point-Of-Care Sensors for Therapeutic Drug Monitoring. THER DRUG MONIT. 2026; 48（SCI Q2）
[3] Detection and degradation of phenolic compounds based on metal-organic complexes[J]. Coordination Chemistry Reviews, 2025, 538: 216721 (SCI Q1，IF=23.5 )
[4] Sensitive fluorescent detection of p-nitrobenzene derivatives with electron-donating groups utilizing an F-rich fluorescent covalent organic framework[J], Microchemical Journal,2025,218:115273. （SCI Q1）
[5] Enhanced specificity in molecular imprinting: A dual-role chitosan-bentonite substrate coupled with hierarchical monomers for ultrasensitive diclofenac potassium and metabolite enrichment [J], International Journal of Biological Macromolecules, 2025,330(3):148144.（SCI Q1）
[6] Establishment and application of a rapid method for the determination of both total and unbound anlotinib concentrations by high-performance liquid chromatography–tandem mass spectrometry [J]. Journal of Chromatography B, 2025, 1256：124555 ( SCI，Q2)
[7] Morphology-dependent magnetic hyperthermia characteristics of Fe3O4 nanoparticles[J]，Materials Chemistry and Physics, 2025, 329, 130045. (SCI Q1)
[8] Unbound concentration of lenvatinib in human plasma as determined by centrifugal ultrafiltration and HPLC-MS/MS: Optimization and validation [J]. Journal of Chromatography B, 2024, 1240: 124157. (SCI Q2)
[9] NIR and magnetism dual-response multi-core magnetic vortex nanoflowers for boosting magneto-photothermal cancer therapy[J]. Nanoscale, 2024, 16(21): 10428-10440. (SCI Q1)
[10] Circular RNAs in programmed cell death: Regulation mechanisms and potential clinical applications in cancer: A review[J]. International Journal of Biological Macromolecules, 2024, 280: 135659. (SCI Q1)
[11] Graphene oxide decorated with MnxCo1-xFe2O4 nanoparticles for highly efficiency magnetic hyperthermia[J]. Materials Chemistry and Physics, 2024, 320: 129477. (SCI Q1)
[12] Hollow spherical Mn0.5Zn0.5Fe2O4 nanoparticles with a magnetic vortex configuration for enhanced magnetic hyperthermia efficacy[J]. Nanoscale, 2023, 15(44), 17946-17955. (SCI Q1)
[13] Multifunctional Mn0.5Zn0.5Fe2O4 nanoparticle/PPy-PEG structures for synergistic photo-magnetic hyperthermia applications[J]. ACS Applied Nano Materials, 2023, 6(19): 18571-18581. ( SCI Q2)
[14] Multiwalled carbon nanotubes decorated with Mn0.5Zn0.5Fe2O4 nanoparticles for magneto-photothermal cancer therapy [J]. ACS Applied Nano Materials, 2023, 6(14): 13330-13341. (SCI Q2)
[15] The light-responsive oxidase-like activity of MIL-125-NH2@Pd and its application in the determination of casein phosphopeptides[J]. CrystEngComm, 2023, 25: 2110-2118. (SCI Q1)
[16] An optimized LC-MS/MS method for quantification of sunitinib and N-desethyl sunitinib in human plasma and its application for therapeutic drug monitoring[J]. Therapeutic Drug Monitoring, 2023, 45(6):817-822. (SCI Q2)
[17] Numerical investigation of the effect of injection sites arrangement on the temperature distribution during magnetic fluid hyperthermia[J]. Journal of Magnetism and Magnetic Materials, 2022, 555: 169393. (SCI Q2)
[18] Heat-generating Mn0.5Zn0.5Fe2O4/MWCNTs nanocomposites for enhancing hyperthermia efficacy in magnetic hyperthermia applications[J]. Journal of Alloys and Compounds, 2022, 926: 166806. (SCI Q2)
[19] Research progress on preparation of pH /temperature-sensitive intelligent hydrogels and its applications in target transport and controlled release fields of drugs. International Journal of Polymer Science, 2021: 1340538. (SCI Q2)
[20] Preparation of magnetic yolk-shell structured metal-organic framework material and its application in pharmacokinetics study of alkaloids[J]. Analytical and Bioanalytical Chemistry, 2021, 413(28): 6987-6999. (SCI Q2)
[21] Metabolomics-based discovery of molecular signatures for triple negative breast cancer in Asian female population[J], Scientific Reports, 2020, 10: 370. (SCI Q1)
[22] 环状RNAs在乳腺癌中的研究进展[J]. 中华乳腺病杂志(电子版), 2020, 14(3):173-179.
[23]免疫检查点抑制剂剂量/暴露-反应的相关性分析[J].中国医院用药评价与分析, 2025, 25(1):117.
二、授权的部分发明专利
[1] 基于HPLC-MS/MS单峰法同时测定人血浆中SUN及SU12662的方法, 发明专利: ZL202210646820.2
[2] PIVAS工作区域细胞毒药物残留清洁方法, 发明专利：ZL202210773675.4
[3] Ultra-high Performance Chromatography Couple with Tandem Mass Spectrometry Method For Measuring Isotope Dilution. 国际发明专利 2021-12-22 授权
[4] 一种测定同位素稀释超高效液相色谱质谱联用方法[P], 发明专利号: ZL202011338317.8
[5] 应用iTRAQ技术研究三阴性乳腺癌外泌体差异表达蛋白的方法[P],发明专利号: ZL201810997414.4
[6] 三阴性乳腺癌特异性环状RNA的筛选方法[P],发明专利号: ZL201710422361.9
[7] 筛选三阴性乳腺癌特异性血清代谢标志物的方法[P], 发明专利号: ZL201610137478.8
[8] 激素受体阳性乳腺癌复发监测基因突变文库的构建方法[P],发明专利号: ZL201710170142.6
[9] 核酸靶序列捕获测序文库的制备方法[P], 发明专利号: ZL201610185978.9
[10] 基于眼动信号的视觉诱导晕动检测方法[P], 发明专利号: ZL201710089641.2
[11] 一种仑伐替尼的未结合浓度测定方法[P],专利号：ZL20231 1342341.2
三、承担的科学研究项目
1.重庆市卫生健康委科卫联合面上项目，2024MSXM037，基于治疗药物监测联合群体药动学模型构建舒尼替尼临床个体化用药策略研究，2024年1月至2025年12月，（项目负责人）。
2.沙坪坝区2023年技术创新与应用发展项目，2023121，基于治疗药物监测（TDM）的精准药学服务新模式探索。（项目负责人）
3.重庆市科学技术局，自然科学基金面上项目,cstc2021jcyj-msxmX0448，环状RNA has-circ-002176调控三阴性乳腺癌耐药的作用机制研究，2021-10-01至2024-09-30.（项目负责人）。
4.中央高校“医工融合”项目, 2019CDYGYB022, 温度-pH-磁三重智能响应微胶囊载药体系在乳腺肿瘤中的靶向输运、定点释放及传质特性研究, 2019-06至2021-05. （项目负责人）。
5.重庆市科学技术局, 重庆市科研院所绩效激励引导专项项目, cstc2017jxjl130006, 基于CircRNA 及组学方法的三阴性乳腺癌作用靶点筛选及其发生机制研究, 2018-01至 2019-12. （项目负责人）。
6.重庆市科学技术局, 重庆市科委基础科学与前沿技术研究(一般), cstc2016jcyjA0144, 三阴性乳腺癌血清代谢组学研究及特异性标志物筛选, 2016-07至2018-06. （项目负责人）。
四、相关奖励与荣誉
[1] 2022年重庆市中青年医学高端人才
[2] 2022 年院级科研表彰二等奖
[3] 2024年院级科技创新先进个人三等奖
[4] 2024 院级“优秀教学工作者”
[5] 2025年讲课比赛院校赛道三等奖
[6]培养的研究生多次获得校级三好学生、一等学业奖学金等
